Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by significant clinical and progression heterogeneity resulting from complex pathophysiological mechanisms. This study aimed at addressing heterogeneity of PD through the integrative analysis of a broad spectrum of data sources. We analyzed clinical progression data spanning over 5 years from individuals with de novo PD, using machine learning and deep learning, to characterize individuals’ phenotypic progression trajectories for subtyping. We discovered three pace subtypes of PD which exhibited distinct progression patterns and were stable over time: the Inching Pace subtype (PD-I) with mild baseline severity and mild progression speed; the Moderate Pace subtype (PD-M) with mild baseline severity but advancing at a moderate progression rate; and the Rapid Pace subtype (PD-R) with the most rapid symptom progression rate. We found that cerebrospinal fluid P-tau/α-synuclein ratio and atrophy in certain brain regions measured by neuroimaging might be indicative markers of these subtypes. Furthermore, through genetic and transcriptomic data analyses enhanced by network medicine approaches, we detected molecular modules associated with each subtype. For instance, the PD-R-specific module suggested STAT3, FYN, BECN1, APOA1, NEDD4, and GATA2 as potential driver genes of PD-R. Pathway analysis suggested that neuroinflammation, oxidative stress, metabolism, AD, PI3K/AKT, and angiogenesis pathways may drive rapid PD progression (i.e., PD-R). Moreover, we identified candidate repurposable drugs via targeting these subtype-specific molecular modules and estimated their treatment effects using two large-scale real-world patient databases. The real-world evidence we gained revealed metformin’s potential in ameliorating PD progression. In conclusion, our findings illuminated distinct PD pace subtypes with differing progression patterns, uncovered potential biological underpinnings driving different subtypes, and predicted repurposable drug candidates. This work may help better understand clinical and pathophysiological complexity of PD progression and accelerate precision medicine.
Competing Interest Statement
J.C. has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. The other authors have declared that no conflict of interest exists.
Funding Statement
We thank the AMP-PD consortium for developing and providing access to the data resource. We thank the PPMI and PDBP cohorts for contributing their data to AMP-PD. This work was supported by following: National Institute on Aging RF1AG072449 and the Michael J. Fox Foundation to F.W.; National Institute on Aging R01AG080991 and R01AG076234 to F.W. and J.B.; National Institute on Aging R01AG076448 to F.W. and F.C.; National Institute on Aging U01AG073323, R21AG083003, R01AG066707, R01AG082118, RF1AG082211, RF1NS133812, 3R01AG066707-01S1, 3R01AG066707-02S1, and R56AG074001 and Alzheimer's Association (ALZDISCOVERY-1051936) to F.C.; National Institute of General Medical Sciences P20GM109025, National Institute of Neurological Disorders and Stroke U01NS093334, National Institute on Aging R01AG053798, P30AG072959, R35AG71476, and AG083721-01, Alzheimer's Disease Drug Discovery Foundation (ADDF), Ted and Maria Quirk Endowment, and Joy Chambers-Grundy Endowment to J.C..
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board approved the PPMI protocol in all participating sites. The institutional review board approved the PDBP protocol in all participating sites. The use of the INSIGHT data was approved by the Institutional Review Board (IRB) of Weill Cornell Medicine under protocol 21-07023759. The use of the OneFlorida+ approved by the IRB of University of Florida under protocol IRB202300639.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We updated RWD analysis in two large-scale cohorts - INSIGHT and OneFlorida, which suggest Metformin as a promising candidate for preventing PD progression.
